Loading...
•
Mar 31, 2025
Nano-X Q1 2025 Earnings Report
Nanox reported a wider net loss despite higher revenue in Q1 2025.
Key Takeaways
Nanox posted a net loss of $13.2M for Q1 2025, with revenue reaching $2.8M. The company received FDA clearance for its updated ARC X system and continued expanding its commercial deployments.
Revenue increased to $2.8M from $2.6M in Q1 2024.
Net loss widened to $13.2M from $12.2M year-over-year.
Received FDA 510(k) clearance for Nanox.ARC X.
Deployed over 60 imaging units across commercial and clinical settings.
Revenue by Segment
Forward Guidance
Nanox expects to increase deployment of units globally to over 100 by year-end, assuming stable macroeconomic conditions.
Positive Outlook
- Targeting over 100 units deployed globally by end of 2025
- Continued strong performance in teleradiology services
- Commercial collaborations to support growth
- FDA clearance for Nanox.ARC X enhances credibility
- Strengthened regulatory and clinical foundation for products
Challenges Ahead
- Ongoing operating losses continue to be significant
- Negative cash flow from operations of $10.3M
- Gross loss margin remains heavily negative on GAAP basis
- Revenue from imaging systems remains minimal
- Dependence on further commercialization to scale revenues
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...